Cochrane · systematic review · CD006418
Isoniazid for preventing tuberculosis in HIV‐infected children
Zunza, M, Gray, DM, Young, T, et al. · Cochrane Database of Systematic Reviews · 2017 · Cochrane Library
Infectious DiseasesAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
4
current version
GRADE rated
4
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 2 · 50%Low 2 · 50%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Isoniazid prophylaxis compared to placebo for HIV‐positive children not on antiretroviral therapy (ART)
Population: HIV‐positive children not taking ART
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Active TB Isoniazid prophylaxis vs placebo | HR 0.31 [0.11, 0.87] | 1 study · 240 participants | Low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Death Isoniazid prophylaxis vs placebo | HR 0.46 [0.22, 0.95] | 1 study · 240 participants | Low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Isoniazid prophylaxis compared to placebo for HIV‐positive children on antiretroviral therapy (ART)
Population: HIV‐positive children on ART
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Active TB Isoniazid prophylaxis vs placebo | RR 0.76 [0.5, 1.14] | 3 studies · 737 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Death Isoniazid prophylaxis vs placebo | RR 1.45 [0.78, 2.72] | 3 studies · 737 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness |